Retrospective Cohort Study on the Impact of PDL Treatment History on the Efficacy of HMME-PDT in Treating PWS Children

Second Affiliated Hospital of Xi'an Jiaotong University273 enrolled

Overview

This retrospective study investigated the influence of prior pulse dye laser (PDL) treatment on the effectiveness of Hemoporfin-PDT in young children aged 1-3 years with PWS. The study population included patients without a history of PDL treatment and patients with a history of PDL treatment.

Background Hemoporfin-mediated photodynamic therapy (Hemoporfin-PDT) is considered a safe and effective treatment for port-wine stains (PWS). This study aims to investigate the influence of prior pulse dye laser (PDL) treatments history on the effectiveness of Hemoporfin-PDT in young children aged 1-3 years with PWS. Methods Data was gathered for individuals with PWS aged 1-3 years who received two or more Hemoporfin-PDT treatments. The study population was stratified into two groups: Cohort 1 (No PDL) comprised patients without a history of PDL treatment, while Cohort 2 (Prior PDL) consisted of patients with a history of PDL treatment. An analysis was conducted to investigate the relationship between treatment efficacy and variables including gender, age, location, and type of PWS.

Study Type

OBSERVATIONAL

Enrollment

273

Conditions

Port-Wine Stain

Interventions

HMME-PDTCOMBINATION_PRODUCT

Twice HMME-PDT, and the treatment interval is 2 to 3 months.

PDLDEVICE

Prior PDL treatment history.

Eligibility

Sex: ALLMin age: 1 YearMax age: 3 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients clinically diagnosed with PWS (Port Wine Stain) who were between 1 and 3 years old at the time of their first HMME-PDT treatment. * Patients who, after evaluation by a clinician, are deemed eligible for HMME-PDT treatment and whose guardians have signed an informed consent form. * Patients who have undergone two or more HMME-PDT treatments. ④ Patients with complete basic information and treatment-related information. Exclusion Criteria: * Exclusion of patients with syndromes associated with PWS. * Exclusion of patients with a history of treatments for PWS other than PDL treatment. * Patients with other vascular malformations. ④ Exclusion of patients who have received any other PWS treatment within 2 months prior to HMME-PDT treatment.

Locations (1)

The Second Affiliated Hospital of Xi'an Jiaotong University

Xi'an, Shaanxi, China

Outcomes

Primary Outcomes

The rate of lesions regression

Two independent blinded assessors assessed treatment efficacy by comparing before and after treatment photos of patients receiving Hemoporfin-PDT for reducing redness. The final outcome was determined as the average of these two assessments. Efficacy was assessed using standard quartiles: Excellent (76-100 %); Good (51-75 %); Fair (26-50 %); Poor (0-25 %).

Time frame: The efficacy evaluation will be conducted 3 months after the completion of the 2nd HMME-PDT treatment.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.